| Abstrakt: |
Keywords: Cancer; Drugs and Therapies; Health and Medicine; Hematology; Ibrutinib Therapy; Immunologic Agents; Immunoproliferative Disorders; Immunotherapy; Kinase Inhibitors; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Monoclonal Antibodies; Obinutuzumab Therapy; Oncology; Pediatrics; Pharmaceuticals; Protein Kinase Inhibitors EN Cancer Drugs and Therapies Health and Medicine Hematology Ibrutinib Therapy Immunologic Agents Immunoproliferative Disorders Immunotherapy Kinase Inhibitors Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Monoclonal Antibodies Obinutuzumab Therapy Oncology Pediatrics Pharmaceuticals Protein Kinase Inhibitors 463 463 1 10/24/23 20231024 NES 231024 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on lymphoma are presented in a new report. Cancer, Drugs and Therapies, Health and Medicine, Hematology, Ibrutinib Therapy, Immunologic Agents, Immunoproliferative Disorders, Immunotherapy, Kinase Inhibitors, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Monoclonal Antibodies, Oncology, Pediatrics, Pharmaceuticals, Protein Kinase Inhibitors, Obinutuzumab Therapy. [Extracted from the article] |
